Jordan Julie 4
4 · Neurogene Inc. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) CMO Julie Jordan Sells 828 Shares
What Happened
Julie Jordan, Chief Medical Officer of Neurogene, sold 828 shares on March 26, 2026. The shares were sold at a weighted-average price of $21.89 for total proceeds of approximately $18,128. This sale was a mandatory portion of an RSU vesting event to satisfy tax withholding; it is not an open discretionary sell decision.
Key Details
- Transaction date: March 26, 2026; Form 4 filed March 30, 2026 (timely within the 2-business-day requirement).
- Sale: 828 shares disposed; weighted-average price $21.89; prices ranged $21.68–$22.19 across multiple executions.
- Proceeds: ~ $18,128.
- Reason/footnote: Sale relates exclusively to mandatory share sale to cover tax withholding on RSU vesting (Footnote F1).
- Holdings after transaction: The filing does not state total shares owned following this sale.
- Additional award detail (Footnote F3): Reporting person has outstanding RSUs — 5,600 units vesting in equal installments on 3/26/2027 and 3/26/2028, and 4,900 units vesting in equal installments on 2/20/2027, 2/20/2028, and 2/20/2029, subject to continued service.
Context
- This was a tax-withholding sale triggered by RSU vesting (a routine administrative sale), not a discretionary open-market liquidation decision. Such mandatory sell-to-cover transactions are common following equity awards and do not necessarily signal insider sentiment about the company.
Insider Transaction Report
Form 4
Neurogene Inc.NGNE
Jordan Julie
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-26$21.89/sh−828$18,128→ 12,472 total
Footnotes (3)
- [F1]On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Signature
/s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan|2026-03-30